Results 11 to 20 of about 136,011 (340)
SAGE Open Medical Case Reports, 2023 Atezolizumab plus bevacizumab is the recommended first-line treatment for unresectable hepatocellular carcinoma, based on guidelines from the Barcelona Clinic Liver Cancer prognosis and treatment strategy.
Takenori Ichimura +4 more
doaj +1 more source
Liver Cancer, 2023 Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due
Masatoshi Kudo +13 more
doaj +1 more source
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
New England Journal of Medicine, 2020 BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with
R. Finn +20 more
semanticscholar +1 more source
Bevacizumab and ovarian cancer [PDF]
Therapeutic Advances in Medical Oncology, 2012 Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor-A, and is indicated in the treatment of various tumors (colon, lung, renal, and glioblastoma). It has been recently approved for the treatment of ovarian cancer in various countries.
Agustin A. Garcia, Harpreet Singh
openaire +7 more sources
Ipilimumab and Bevacizumab in Glioblastoma [PDF]
Clinical Oncology, 2016 The median survival in glioblastoma is just over a year, with no standard second-line therapy. Ipilimumab is an immune checkpoint inhibitor that activates the anti-tumour immune response by cytotoxic T-lymphocyte antigen-4 blockade. There is significant evidence supporting its role in the treatment of malignant melanoma, including in patients with ...
Thomas Carter +5 more
openaire +5 more sources
Annals of Gastroenterological Surgery, Volume 7, Issue 1, Page 81-90, January 2023., 2023 XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS and measures of safety met current standards.
Chu Matsuda +16 more
wiley +1 more source
Current status of liver transplantation for non‐B non‐C liver cirrhosis and hepatocellular carcinoma
Annals of Gastroenterological Surgery, Volume 7, Issue 1, Page 42-52, January 2023., 2023 Recently, the cases of LT for non‐B non‐C cirrhosis and HCC have been increasing in Japan as well as worldwide. Perioperative management of non‐B non‐C liver disease is problematic due to various risk factors, including alcohol consumption and metabolic syndrome‐related risks, such as obesity and diabetes mellitus.
Takahiro Nishio +4 more
wiley +1 more source
Hepatology, 2022 Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in routine clinical practice in patients with impaired liver function.
A. D’Alessio +34 more
semanticscholar +1 more source
Bevacizumab for recurrent ependymoma [PDF]
Neurology, 2009 2060 Background: Ependymoma is a rare type of glioma, representing less than 5% of brain tumors in adults. Radiotherapy (RT) is commonly administered, but there is no standard chemotherapy. At recurrence ependymoma is notoriously refractory to therapy and the prognosis is poor.
Andrew B. Lassman +7 more
openaire +4 more sources
Cancer Medicine, Volume 11, Issue 24, Page 4880-4888, December 2022., 2022 Kaplan–Meier analysis demonstrated that patients with splenomegaly had worse OS than those without splenomegaly. Abstract Background & aims Immune checkpoint inhibitors (ICIs) play an increasingly important role in the treatment of primary liver cancer (PLC). Some patients with PLC experience symptoms of splenomegaly.
Lu‐Shan Xiao +9 more
wiley +1 more source